Insider Selling: Foundation Medicine, Inc. (NASDAQ:FMI) Insider Sells $245,313.44 in Stock

Foundation Medicine, Inc. (NASDAQ:FMI) insider David Daly sold 6,316 shares of Foundation Medicine stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $38.84, for a total transaction of $245,313.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

David Daly also recently made the following trade(s):

  • On Thursday, June 1st, David Daly sold 555 shares of Foundation Medicine stock. The shares were sold at an average price of $38.30, for a total transaction of $21,256.50.

Foundation Medicine, Inc. (FMI) opened at 39.35 on Wednesday. The stock has a 50 day moving average of $39.19 and a 200-day moving average of $29.62. The stock’s market cap is $1.40 billion. Foundation Medicine, Inc. has a 12 month low of $17.10 and a 12 month high of $43.15.

Foundation Medicine (NASDAQ:FMI) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by $0.29. Foundation Medicine had a negative return on equity of 80.75% and a negative net margin of 126.17%. The company had revenue of $26.32 million for the quarter, compared to analyst estimates of $29.07 million. During the same period in the previous year, the business posted ($0.50) EPS. The firm’s revenue for the quarter was down 13.3% compared to the same quarter last year. On average, equities analysts forecast that Foundation Medicine, Inc. will post ($4.34) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Foundation Medicine, Inc. (NASDAQ:FMI) Insider Sells $245,313.44 in Stock” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/07/12/insider-selling-foundation-medicine-inc-nasdaqfmi-insider-sells-245313-44-in-stock.html.

Institutional investors have recently made changes to their positions in the company. Creative Planning raised its position in Foundation Medicine by 10.0% in the first quarter. Creative Planning now owns 4,400 shares of the company’s stock worth $142,000 after buying an additional 400 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Foundation Medicine by 5.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,898 shares of the company’s stock worth $193,000 after buying an additional 583 shares during the period. Bank of America Corp DE raised its position in Foundation Medicine by 65.8% in the first quarter. Bank of America Corp DE now owns 6,180 shares of the company’s stock worth $200,000 after buying an additional 2,452 shares during the period. GSA Capital Partners LLP raised its position in Foundation Medicine by 24.1% in the fourth quarter. GSA Capital Partners LLP now owns 11,500 shares of the company’s stock worth $204,000 after buying an additional 2,234 shares during the period. Finally, State Board of Administration of Florida Retirement System purchased a new position in Foundation Medicine during the first quarter worth $218,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

Several research firms have recently commented on FMI. BidaskClub lowered shares of Foundation Medicine from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 5th. ValuEngine upgraded shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Thursday, April 6th. BTIG Research upgraded shares of Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 price target for the company in a report on Monday, May 15th. Finally, William Blair restated a “buy” rating on shares of Foundation Medicine in a report on Monday, April 3rd. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Foundation Medicine has a consensus rating of “Hold” and a consensus price target of $30.25.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply